Article Information
History
- December 6, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Antonin Bal, PharmD1,2,*,#,
- Grégory Destras, PharmD1,2,*,
- Bruno Simon, MD1,2,*,
- Jean-Marc Giannoli, PharmD3,
- Florence Morfin, PharmD PhD1,2,
- Bruno Lina, MD PhD1,2,
- Laurence Josset, PharmD PhD1,2,
- IVAC study group
- 1Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- 2CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France
- 3DYOMEDEA-NEOLAB-Biogroup – Plateau technique de la Sauvegarde, Lyon, France
- ↵#Corresponding authors: Antonin Bal, Associate Professor, University Hospital of Lyon, France, National reference center for respiratory viruses, Lyon, France, Phone: 04-72-07-16-98, Mail: antonin.bal{at}chu-lyon.fr
↵* equal contributions
Posted December 06, 2021.
Investigation of Vaccine Breakthrough Infections by Vaccine strategy during the Delta Variant Wave in France
